KRAS and colorectal neoplasm: This susceptibility is based not only on genetic markers but also on distinct metabolic behaviors, a notion supported by Rebane-Klemm et al., who found metabolic phenotype variations in colorectal tumors with KRAS and BRAF mutations [28].